Navigation Links
Questcor to Report Second Quarter Results on July 24, 2012
Date:7/10/2012

ANAHEIM, Calif., July 10, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release second quarter 2012 financial results on Tuesday, July 24, 2012 after the close of the U.S. financial markets. The Company will host a conference call and slide presentation via webcast on Tuesday, July 24, 2012 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the quarter, as well as current corporate developments. The call can be accessed in the following ways:

  • By webcast: At Questcor's investor relations website: http://ir.questcor.com/.
  • By telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 877-941-9205. For participants outside the U.S., the dial-in number is 480-629-9819.
  • By audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.  The dial-in number for U.S. participants is 800-406-7325. For participants outside the U.S., the replay dial-in number is 303-590-3030. The replay access code for all callers is 4550797#.

About Questcor                                                                                     

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also currently preparing to launch a pilot effort in rheumatology, as Acthar is approved for several rheumatology-related conditions including Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.    For more information about Questcor, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Chindex International, Inc. to Report First Quarter 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July 25, 2017 ... repurposing drugs to treat rare nervous system diseases, has concluded ... develop and market the drug SOM0226 against transthyretin amyloidosis (ATTR). ... very promising results in a Phase 2 study conducted in ... office in the United States ...
(Date:7/24/2017)... July 24, 2017 IBM (NYSE: IBM ) ... Quadrant for Solid-State Arrays (SSA) for the fourth year in ... According to Gartner, "Vendors in the Leaders quadrant have the ... Vision. A vendor in the Leaders quadrant has the market ... the acceptance of new technologies. These vendors demonstrate a clear ...
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 /PRNewswire/ ... University of Alberta in Edmonton, Canada ... partner journal, Schizophrenia 1 , demonstrating that AI ... schizophrenia with 74% accuracy. This retrospective analysis also ... symptoms in schizophrenia patients with significant correlation, based ...
Breaking Medicine Technology:
(Date:7/25/2017)... OK (PRWEB) , ... July 25, 2017 , ... ... proud to announce the launch of their partnership to provide the Pharmacist ... the first pharmacy-focused platform in the country with the ability to develop the ...
(Date:7/25/2017)... ... July 25, 2017 , ... Therachat ... will be exhibiting and providing demos of its smart journaling platform at the ... Center in Washington D.C. from August 3-6, 2017. , The APA Annual Convention ...
(Date:7/25/2017)... , ... July 25, 2017 , ... ... ATM provider in the United States, today announced its partnership with financial technology ... , The foundation of the solution lies within Hyosung’s superior ATMs, assisted ...
(Date:7/25/2017)... Jacksonville, Fla. (PRWEB) , ... July 25, 2017 , ... ... employee and father Ezra Clark is taking advantage of a new benefit for employees ... “It really means a lot that the company supports me and other employees as ...
(Date:7/25/2017)... TX (PRWEB) , ... July 25, 2017 , ... SignatureCare ... emergencies in the Austin, TX area 24 Hours a day. , The ... Austin, TX. , “We’ve been open four months now and things are running ...
Breaking Medicine News(10 mins):